CliffBio
small molecule

XENON XE 133

XENON XE-133

Loss of exclusivity—loss of exclusivity
CompanyCurium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameXENON XE 133
Active ingredientXENON XE-133
Strength20mCi/VIAL
Dosage formGAS
RouteINHALATION
ModalitySmall molecule
FDA approvalMarch 1982
Marketing statusRX

More from Curium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.